-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benzinga·06/11/2024 11:33:29
Listen to the news
Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.